Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
A phase 1/2 trial of Rituximab and Ibrutinib in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.
Overview
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL is a phase 1/2 interventional study registered as NCT04494503 by Ascentage Pharma Group Inc., with 123 participants planned, started 2020-08-31 and due to reach its primary completion in 2024-10-20. Interventions recorded: APG-2575, Rituximab and Ibrutinib.
Similar pages
not linked directly; found by shared links- TrialStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Shares Ascentage Pharma and the tag pipeline.